用AI分析超声影像,非侵入式精准评估肺高压进展
AI-Enabled Accurate Non-Invasive Assessment of Pulmonary Hypertension Progression via Multi-Modal Echocardiography
- 构建多模态视觉语言模型,融合多视角超声视频与频谱图
- 对肺动脉压和阻力估计误差降低近一半,外院验证误差仅3.147
- 可预测治疗效果,适合临床监测与个性化诊疗决策
超声心动图可检测肺高压,但评估进展常不准确。右心导管检查虽为金标准,却具侵入性,难以用于常规随访。本文提出MePH模型,基于12家医院的1237例患者数据(含标准化超声视频、频谱图像及右心导管数据),首次精确建模非侵入性多视图多模态超声与右心导管测得压力、阻力之间的关系。MePH在估测平均肺动脉压(mPAP)和肺血管阻力(PVR)上,分别比超声医师降低49.73%和43.81%的平均绝对误差。在8家独立外部医院测试中,PVR预测平均绝对误差为3.147。其受试者工作特征曲线下面积达0.921,优于超声医师的0.842,无论轻度或重度肺高压均能准确判断严重程度。前瞻性研究证实该模型可预测治疗效果。本研究为肺高压患者提供了一种非侵入、及时的疾病监测新方法,显著提升管理精度与效率,助力早期干预与个体化治疗。
原文摘要 · Abstract (English)
Echocardiographers can detect pulmonary hypertension using Doppler echocardiography; however, accurately assessing its progression often proves challenging. Right heart catheterization (RHC), the gold standard for precise evaluation, is invasive and unsuitable for routine use, limiting its practicality for timely diagnosis and monitoring of pulmonary hypertension progression. Here, we propose MePH, a multi-view, multi-modal vision-language model to accurately assess pulmonary hypertension progression using non-invasive echocardiography. We constructed a large dataset comprising paired standardized echocardiogram videos, spectral images and RHC data, covering 1,237 patient cases from 12 medical centers. For the first time, MePH precisely models the correlation between non-invasive multi-view, multi-modal echocardiography and the pressure and resistance obtained via RHC. We show that MePH significantly outperforms echocardiographers' assessments using echocardiography, reducing the mean absolute error in estimating mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) by 49.73% and 43.81%, respectively. In eight independent external hospitals, MePH achieved a mean absolute error of 3.147 for PVR assessment. Furthermore, MePH achieved an area under the curve of 0.921, surpassing echocardiographers (area under the curve of 0.842) in accurately predicting the severity of pulmonary hypertension, whether mild or severe. A prospective study demonstrated that MePH can predict treatment efficacy for patients. Our work provides pulmonary hypertension patients with a non-invasive and timely method for monitoring disease progression, improving the accuracy and efficiency of pulmonary hypertension management while enabling earlier interventions and more personalized treatment decisions.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。